MSD, known as Merck & Co in the US and Canada, licensed rights to Lenvima in 2018 in a near-$6 billion deal aimed at ...

The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...

At ESMO this year, AstraZeneca presented final overall survival results from the MATTERHORN Phase III Trial for patients with ...

BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG ...

CSL's already depressed share price sank further on the news of the delay, which chairman Dr Brian McNamee said was related ...

Eli Lilly and tech giant NVIDIA have joined forces on an ambitious plan – building the most powerful AI-powered supercomputer ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences ...

Shares in Novartis had fallen nearly 3.5% at the time of writing, as investors digested the third-quarter figures and ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

Nex-z is one of two late-stage projects on the go at Intellia, a specialist in CRISPR gene-editing co-founded by Nobel Prize ...

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

The suit also accuses J&J of anticipating that the link between Tylenol and autism would be thrust into the spotlight by the ...